Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

The Digital Dose Inhalers Market is set for strong growth through 2031, driven by rising respiratory diseases and demand for smart, accurate drug delivery.

With that, Theravance expects its lifetime value from the inhaler to come out to $1.52 billion. The drug stems from a 2002 ...

Patients with COPD and established cardiovascular disease have more MACEs and seek less preventive cardiac care than patients with CVD alone.

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

Economic Hardship Reporting Project and The Nation examined how a lack of federal funding and climate change severely impact ...

The programs, in which EMS workers make home visits to patients, have helped curb expensive hospital visits, providers say.

Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...

In a study spanning decades and thousands of participants, scientists from Finland and the UK have found that even modest non ...

The Kee Tas Kee Now Tribal Council has updated a wildfire alert, cancelling the two-hour evacuation alert for the Whitefish ...